Provepharm signs license agreement with Daiichi Sankyo to provide methylthioninium chloride Proveblue solution for injection to Japan
Daiichi Sankyo will resolve the unmet need for an approved methylthioninium chloride injectable drug in Japan
Provepharm announced that it has entered into an exclusive licensing agreement with Daiichi Sankyo to make Provepharm’s injectable medicinal product, Methylthioninium chloride Proveblue, available in Japan. The Proveblue medicinal product is used for the treatment of methaemoglobinaemia induced by life-threatening medicinal and chemical products.
Under this agreement Provepharm grants Daiichi Sankyo exclusive rights to methylthioninium chloride Proveblue solution for injection in Japan. Daiichi Sankyo will be responsible for the submission of a marketing authorization application and for all commercial activities relating to the product in this country. Commercial terms of the deal were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program
BASF introduces extended solubilization and dermatology excipients portfolios
Researchers from BGU have generated a promising drug candidate for the treatment of Psoriasis
Transgene Receives FDA Fast Track Status for TG4010 for Treatment of Non-Small Cell Lung Cancer
Antisoma's phase III trial of AS1413 completes patient enrolment
EMBO recognizes 63 researchers for advances in life sciences
Sensitizing tumor response to cancer therapy
PANATecs GmbH Appoints Rainer Baule, Chairman of the Board of Fresenius Kabi AG, to the Advisory Board

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Wyss Institute at Harvard University launches SPEAR Bio - Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples
